Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.61 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.61 |
| ▸ | JUN | P05412 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659102 | 1.00 | RAB9A (0.74) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL4400320 | 0.85 | MAPT (1.00) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL977480 | 0.85 | MAPT (1.00) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL12257967 | 0.84 | MAPT (0.90) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL979409 | 0.83 | CYP1B1 (0.83) | RAB9AKDM4EMAPTNPC1LMNA | |
| SCHEMBL9221198 | 0.83 | NPC1 (0.81) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL7368933 | 0.83 | CYP1B1 (0.83) | RAB9AKDM4EMAPTNPC1LMNA | |
| SCHEMBL9221208 | 0.83 | NPC1 (0.81) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL4178737 | 0.80 | MAPT (0.62) | RAB9AKDM4EMAPTNPC1PKM | |
| SCHEMBL4181070 | 0.80 | MAPT (0.62) | RAB9AKDM4EMAPTNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | RAB9A 149/4885KDM4E 2074/4885MAPT 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.